Quantitative assessment of Exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 3, 2010, Pages 336-344

  Ravva, P ^a   Gastonguay, M R ^b   French, J L ^a   Tensfeldt, T G ^a   Faessel, H M ^a  

^a PFIZER INC   (United States)

^b Metrum Research Group LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARENICLINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MULTICENTER STUDY; NAUSEA; POPULATION EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SEX DIFFERENCE; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; QUINOXALINES; RISK ASSESSMENT; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77149126403     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.282     Document Type: Article

References (38)

1. Ezzati, M. & Lopez, a.D. Estimates of global mortality attributable to smoking in 2000. Lancet 362, 847-852 (2003)
2. The Health Consequences of Smoking: A Report of the Surgeon General (US Department of health and human Services, Public health Service, Office of the Surgeon General, Rockville, MD, 2004).
3. World Health Report: Quantifying Selected Major Risks to Health (World health Organization, Geneva, 2002).
4. Coe, J.W. et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48, 3474-3477 (2005)
5. Rollema, H. et al. Pharmacological profle of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an efective smoking cessation aid. Neuropharmacology. 52, 985-994 (2007).
6. Obach, R.S. et al. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab. Dispos. 34, 121-130 (2006)
7. Faessel, H.M., Smith, B.J., Gibbs, M.A., Gobey, J.S., Clark, D.J. & Burstein, A.H. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J. Clin. Pharmacol. 46, 991-998 (2006)
8. Faessel, H.M., Gibbs, M.A., Clark, D.J., Rohrbacher, K., Stolar, M. & Burstein, A.H. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J. Clin. Pharmacol. 46, 1439-1448 (2006).
9. Ravva, P., Gastonguay, M.R., Tensfeldt, T.G. & Faessel, H.M. Population pharmacokinetic analysis of varenicline in adult smokers. Br. J. Clin. Pharmacol. 68, 669-681 (2009).
10. Nides, M. et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow-up. Arch. Intern. Med. 166, 1561-1568 (2006)
11. Oncken, C. et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med. 166, 1571-1577 (2006).
12. Gonzales, D. et al.; Varenicline Phase 3 Study Group. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 296, 47-55 (2006).
13. Jorenby, D.E. et al.; Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 296, 56-63 (2006).
14. Williams, K.E., Reeves, K.R., Billing, C.B. Jr, Pennington, A.M. & Gong, J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr. Med. Res. Opin. 23, 793-801 (2007).
15. Chantix USPI [package insert]. New York, NY: Pfzer Inc., 2009.
16. Johnston, J.A., Fiedler-Kelly, J., Glover, E.D., Sachs, D.P., Grasela, T.h. & DeVeaugh-Geiss, J. Relationship between drug exposure and the Efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob. Res. 3, 131-140 (2001).
17. Heatherton, T.F., Kozlowski, L.T., Frecker, R.C. & Fagerström, K.O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br. J. Addict. 86, 1119-1127 (1991)
18. Kabat, G.C. & Wynder, E.L. Determinants of quitting smoking. Am. J. Public Health 77, 1301-1305 (1987).
19. Yano, I., Beal, S.L. & Sheiner, L.B. The need for mixed-efects modeling with population dichotomous data. J. Pharmacokinet. Pharmacodyn. 28, 389-412 (2001).
20. Bhattaram, V.A. et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin. Pharmacol. Ther. 81, 213-221 (2007).
21. Nakamura, M., Oshima, A., Fujimoto, Y., Maruyama, N., Ishibashi, T. & Reeves, K.R. Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin. Ther. 29, 1040-1056 (2007).
22. Rigotti, N., Pipe, A., Garza, D., Arteaga, C., Benowitz, N. & Tonstad, S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. J. Am. Coll. Cardiol. 53 (suppl. 1), a224 (2009).
23. Karlsson, M.O. & Savic, R.M. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82, 17-20 (2007)
24. Agresti, A. Categorical Data Analysis (John Wiley & Sons, New York, 1990).
25. Gomeni, R., Teneggi, V., Iavarone, L., Squassante, L. & Bye, A. Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: indirect response and probabilistic modeling. Pharm. Res. 18, 537-543 (2001).
26. Kalbfeisch, J.G. Probability and Statistical Inference-Volume 1: Probability (Springer, New York, 1985).
27. Wand, M. et al. SemiPar 1.0., R package. (2005).
28. Ruppert, D., Wand, M.P. & Caroll, R.J. Semiparametric Regression (cambridge University Press, New York, 2003).
29. Burnham, K.P. & anderson, D.R. Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach (Springer, New York, 2002).
30. Harrell, F.E. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis (Springer, New York, 2001).
31. Parke, J., Holford, N.H. & charles, B.G. A procedure for generating bootstrap samples for the validation of nonlinear mixed-efects population models. Comput. Methods Programs Biomed. 59, 19-29 (1999).
32. Karlsson, M.O. et al. A pharmacodynamic Markov mixed-efects model for the efect of temazepam on sleep. Clin. Pharmacol. Ther. 68, 175-188 (2000)
33. Ware, L.H. & Lipsitz, S. Issues in the analysis of repeated categorical outcomes. Stat. Med. 7, 95-107 (1988).
34. Mandema, J.W., Verotta, D. & Sheiner, L.B. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate efects. J. Pharmacokinet. Biopharm. 20, 511-528 (1992).
35. Efron, B. Missing data, imputation, and the bootstrap. J. Am. Stat. Assoc. 89, 463-479 (1994).
36. Ette, E.I. & Onyiah, L.c. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization. Eur. J. Drug Metab. Pharmacokinet. 27, 213-224 (2002).
37. Yafune, A. & Ishiguro M. Bootstrap approach for constructing confdence intervals for population pharmacokinetic parameters. I: a use of bootstrap standard error. Stat. Med. 18; 581-599 (1999).
38. Gelman, a., carlin, J.B., Stern, h.S. & Rubin, D.B. Bayesian Data Analysis 2nd edn. (cRc Press, Boca Raton, FL, 2004).